Investigational drugs reduce risk of death from Ebola virus disease


Investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo (DRC). 

Content Information

Content Author: 
unknown

Content Source: 
US National Institute of Allergy and Infectious Diseases (NIAID)

Content Type: 
News